SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-22-123601
Filing Date
2022-04-27
Accepted
2022-04-27 16:07:52
Documents
8

Document Format Files

Seq Description Document Type Size
1 DEFA14A d283962ddefa14a.htm DEFA14A 28094
2 GRAPHIC g283962g08v06.jpg GRAPHIC 888
3 GRAPHIC g283962g30x46.jpg GRAPHIC 1192
4 GRAPHIC g283962g42i27.jpg GRAPHIC 2541
5 GRAPHIC g283962g61z87.jpg GRAPHIC 1376
6 GRAPHIC g283962g75a36.jpg GRAPHIC 1282
7 GRAPHIC g283962g89p37.jpg GRAPHIC 958
8 GRAPHIC g283962g90f94.jpg GRAPHIC 1273
  Complete submission text file 0001193125-22-123601.txt   43232
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39269 | Film No.: 22859568
SIC: 2834 Pharmaceutical Preparations